This off-target effect casts a cautionary note on their use as chemical probes for SHP2 and suggests a therapeutic framework for improving treatment of RAS-MAPK mutant–driven cancers through intentional exploitation of off-target SHP2-AIs. The gene discussed is PTPN11; the disease is cancer.